Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
61 hedge funds and large institutions have $8.79M invested in Oncternal Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 18 closing their positions.
4.52% less ownership
Funds ownership: 23.05% → 18.53% (-4.5%)
19% less funds holding
Funds holding: 75 → 61 (-14)
30% less capital invested
Capital invested by funds: $12.6M → $8.79M (-$3.85M)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
78% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$781K |
| 2 |
Renaissance Technologies
New York
|
+$360K |
| 3 |
Two Sigma Investments
New York
|
+$220K |
| 4 |
Two Sigma Advisers
New York
|
+$172K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.25M |
| 2 |
Millennium Management
New York
|
-$763K |
| 3 |
Morgan Stanley
New York
|
-$402K |
| 4 |
Goldman Sachs
New York
|
-$189K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$160K |
ONCT Hedge Fund Activity: Q3 2022 in Review
61 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2022, worth a combined $8.79M — down 30% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ONCT and 4 opened new positions — a net loss of 14 holders — while 19 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $781K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.25M sold.
- 61 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2022, down from 75 in Q2 2022.
- Funds reported $8.79M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2022, down 30% quarter-over-quarter.
- 4 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of -14 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $781K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2022 was Citadel Advisors, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2022.